BACKGROUND Pre-reperfusion administration of intravenous (IV) metoprolol reduces infarct size in ST-segment elevation myocardial infarction (STEMI).
T imely reperfusion is the mainstay treatment for patients presenting with ST-segment elevation myocardial infarction (STEMI). The preferred reperfusion strategy is primary percutaneous coronary intervention (PPCI), ideally within 120 min of STEMI diagnosis (1, 2) . Adjunct treatments for patients undergoing PPCI are mainly aimed at preventing thrombotic complications, not reducing myocardial loss per se. Myocardial infarct size (MIS) is a major determinant of post-STEMI mortality and morbidity (3) . Patients with a large MIS and associated left ventricular (LV) systolic dysfunction are at high risk of long-term heart failure (HF) readmission and sudden death (4) .
Indeed, post-STEMI severe LV dysfunction is a Class I indication for insertion of an implantable cardioverter-defibrillator (ICD) (5) .
Administration of 15 mg intravenous (IV) metoprolol before reperfusion in STEMI patients undergoing PPCI was recently shown to reduce cardiac magnetic resonance (CMR)-measured infarct size in the METOCARD-CNIC (effect of METOprolol of CARDioproteCtioN during an acute myocardial InfarCtion) trial (6) .
Besides reducing acute infarct size, pre-reperfusion 15 mg metoprolol administration was associated with improved long-term LV systolic function, fewer indications for ICD insertion, and fewer HF readmissions (7) . In the METOCARD-CNIC trial, patients were recruited and randomized to 15 mg IV metoprolol or control before arterial access, either during ambulance transit or at the PPCI hospital. Patients allocated to IV metoprolol therefore received the drug at varying intervals before reperfusion. No previous evaluation has considered the cardioprotective effect of the timing of pre-reperfusion metoprolol administration (long or short pre-reperfusion interval). Identifying the best timing and setting for metoprolol administration for attaining cardioprotection (the out-ofhospital setting or the more controlled hospital/ catheterization laboratory environment) has implications for the chain of care for STEMI patients. Patients with anterior STEMI undergoing PPCI were recruited within the METOCARD-CNIC trial (6) .
Patients underwent 2 CMR studies 5 to 7 days and 6 months after STEMI. Inclusion/exclusion criteria and the study protocol have been published previously (8) .
Briefly, METOCARD-CNIC is a randomized clinical trial that recruited patients with first anterior STEMI who presented early (<6 h from symptom onset) and were undergoing PPCI. Patients were randomized to receive 15 mg IV metoprolol or control before reperfusion. Drs. García-Ruiz and García-Alvarez were CNIC-Cardiojoven fellows. Dr. Fernández-Jiménez was the recipient of nonoverlapping grants from the Ministry of Economy and Competitiveness through the Instituto de Salud Carlos III (Rio Hortega fellowship) 5 to 7 days post-infarction (6); secondary endpoints included LV performance assessed by CMR at 6 months post-infarction (7) . A total of 270 patients were recruited to the METOCARD-CNIC trial, 220 of whom underwent CMR for MIS quantification. Patients with complete 5-to 7-day CMR and time period data (n ¼ 218) were included in this analysis. To study the effect of metoprolol timing on cardioprotection, we divided patients allocated to IV metoprolol into 2 groups according to whether the metoprolol-toreperfusion interval was longer (long-interval group) or shorter (short-interval group) than the median value.
The primary endpoint was MIS assessed by CMR at
The CMR protocol and methods for imaging analysis are described in detail elsewhere (8) .
ANIMAL STUDY DESIGN. Experiments were performed in castrated male Large-White pigs, and MI was induced experimentally by closed-chest, 45-min left anterior descending (LAD) coronary artery occlusion followed by chronic reperfusion. Animals were allocated 1:1:1:1 in a blinded fashion by adaptive randomization to the following treatments: 1) vehicle (control-vehicle group); 2) IV metoprolol (0.75 mg/kg) 25 min before reperfusion (long-interval group);
3) the same metoprolol bolus given 5 min before reperfusion (short-interval group); and 4) IV metoprolol held until 60 min after reperfusion Images were acquired with the use of electrocardiogram gating by operators blinded to the study arm.
Segmented cine steady-state free precession was performed to acquire 11 to 13 contiguous short-axis slices covering the heart from the base to the apex to evaluate global and regional LV motion. CMR parameters can be found in the Online Appendix. The analysis protocol has been detailed elsewhere (9) .
Briefly, LV cardiac borders were traced in each shortaxis cine image to obtain LV end-diastolic volume, LV end-systolic volume, and LVEF. LV volumes and mass were normalized to body surface area according to Brody's formula (12) . CMR post-processing is described in the Online Appendix. Table 1 .
TIME-BASED EFFECT OF IV METOPROLOL ON MIS.
Infarct size was calculated as percentage of left ventricular mass (%LV). Mean values in the long-interval, short-interval, and control groups were 19.3 AE 10.7%, Table 2 .
The consistency of the results was checked with 2 sensitivity analyses. First, analysis of patients allocated to IV metoprolol showed that the sooner the drug was administered, the smaller the MIS and higher the LVEF: every 10 min of "on-board" metoprolol was associated with an MIS reduction of 1.1 g (95% CI: À2.1 to 0.0 g; p ¼ 0.049) and an increase in LVEF of 0.6% (95% CI: À0.1% to 1.2%; p ¼ 0.092) at 5 days post-reperfusion ( Table 3 , Figure 3A) . Second, the analysis was replicated in the complete cohort, using randomization-to-reperfusion time instead of IV metoprolol-to-reperfusion time (see the Methods section); this analysis showed an effect modification (interaction) between IV metoprolol treatment and randomization-to-reperfusion time ( Figure 3B ). Figure 4A) . Full CMR-derived data are presented in Table 4 . After reviewing these hypothesis-generating data, we conducted a large animal (pig) study specifically designed to confirm the hypothesis. Pigs undergoing experimental myocardial ischemia/reperfusion were randomized to receive vehicle or IV metoprolol with a long or short interval before reperfusion, or after reperfusion. Animals receiving IV metoprolol long before reperfusion had significantly smaller infarcts at short term and a better long-term LV performance than the other groups, consistent with the results of the clinical study. Our results suggested that, in patients with no contraindications, the sooner metoprolol is injected in the course of STEMI, the greater the protection against myocardial death.
We previously demonstrated, using the same animal model, that metoprolol reduces infarct size (13) , but only when administered before reperfusion (14) . These studies, which set the basis for the pressure <120 mm Hg, or any degree of atrioventricular block (8) . Patients in the IV metoprolol and control arms showed no differences in the incidence of side effects, including cardiogenic shock (6). Bold indicates statistical significance. *In the IV metoprolol group (adjusted for total ischemic time). †Infarct size normalized by myocardium at risk at 5-day CMR. Tables 1 and 2 . Absence of increased metoprolol-related side effects was also apparent in a separate analysis of the subgroup of patients recruited in the out-of-hospital setting (19) .
Abbreviations as in
The METOCARD-CNIC clinical trial was the first to compare 2 different strategies of b-blocker administration/initiation in STEMI patients undergoing PPCI: IV metoprolol before reperfusion versus LVEDV ¼ left ventricular end-diastolic volume; LVESV ¼ left ventricular end-systolic volume; other abbreviations as in Table 2 .
García-Ruiz et al. The likely explanation for this difference is that patients in the short-interval group were diagnosed either at the PPCI hospital or close to it, whereas patients in the long-interval group were likely diagnosed far from the PPCI center.
The results thus indicated that early IV metoprolol has a greater cardioprotective effect when followed by a period of continued ischemia before reperfusion, a showed that after normalizing for total ischemia duration, every 10 min of onboard metoprolol reduced infarct size by 1.1 g ( Table 3 ). Further analysis of the METOCARD-CNIC cohort has indicated strong benefits of early IV metoprolol in the subpopulation of STEMI patients treated in the out-of-hospital setting (19) .
This phenomenon is being explored further in the ongoing EARLY BAMI (Early Beta blocker Using the same animal model, we previously identified pre-reperfusion metoprolol as a strategy able to reduce infarct size (6) and subsequently proposed amelioration of reperfusion injury as the mechanism underlying this effect (14) . Preliminary results, led by our group, showed that IV adminis- The administration of intravenous (IV) metoprolol before reperfusion reduces infarct size in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary angioplasty. However, the cardioprotective effect of metoprolol varies depending on the timing of its administration during ongoing ischemia. The longer the period of onboard metoprolol before reperfusion, the greater the reduction of infarct and the better the long-term left ventricular ejection fraction (LVEF). On the basis of these data, the earlier metoprolol is administered after STEMI diagnosis, the higher the cardioprotection. Cath lab ¼ catheterization laboratory.
García-Ruiz et al. 
CONCLUSIONS
This study showed that in STEMI patients scheduled for PPCI, the longer the interval between IV metoprolol bolus and reperfusion, the higher the cardioprotection afforded by metoprolol, resulting in smaller infarct size and higher LVEF. These clinical results were validated in a pig study, in which metoprolol administration long before reperfusion was associated with smaller infarcts and better longterm LVEF. Given that reperfusion should not be delayed under any circumstance, the best strategy for attaining cardioprotection with metoprolol is to inject an IV bolus (15 mg according to the METOCARD-CNIC trial) immediately after STEMI diagnosis in patients with no contraindications.
